RxDoctor Payments Data

Brian Saluck, DO

Interventional Cardiology · The Villages, FLNPI 1295796902

Payments from drug & device makers

$29,407in general payments, 2019–2025

Across 601 payments — averaging $48.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$16K
  • Medtronic$4K
  • Penumbra, Inc.$2K
  • Abbott$1K
  • Pfizer$897
  • Boston Scientific$687
  • plus $5K from 43 others

What the payments were for

  • Consulting fees$3601%
  • Speaking & faculty fees$15,06051%
  • Travel & lodging$3,16911%
  • Food & beverage$10,69536%
  • Education$850%
  • Other$380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,407 in reported general payments places this provider in the 70th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,652,607
Medicare patients
1,707
Services billed
12,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban885$1,197,679
EntrestoSacubitril/Valsartan191$305,530
XareltoRivaroxaban193$259,455
Repatha SureclickEvolocumab155$187,132
JardianceEmpagliflozin124$155,448
MultaqDronedarone Hcl38$70,154
BrilintaTicagrelor58$46,537
Praluent PenAlirocumab48$39,657
FarxigaDapagliflozin Propanediol25$33,319
Repatha SyringeEvolocumab18$20,848
NexletolBempedoic Acid21$20,183
Valsartan492$15,321
VerquvoVericiguat14$14,895
Metoprolol Succinate733$10,679
Prasugrel Hcl74$8,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$897$1,197,679885 claims
NovartisEntresto$455$305,530191 claims
Johnson & JohnsonXarelto$488$259,455193 claims
Boehringer IngelheimJardiance$127$155,448124 claims
AstraZenecaBrilinta, Farxiga$492$79,85683 claims
Sanofi-aventis U.S. LLCMultaq$131$70,15438 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$15,602$27,28133 claims
MerckVerquvo$83$14,89514 claims
Arbor Pharmaceuticals, Inc.Edarbi$11$6,34213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →